# A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers

> **NCT01173549** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 26 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Canagliflozin/Placebo Placebo/Canagliflozin
- **OTHER:** no intervention

## Key facts

- **NCT ID:** NCT01173549
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** —
- **Final completion:** 2011-09
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2012-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01173549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01173549, "A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01173549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*